G G Kovacs1, G Respondek2,3, T van Eimeren4,5,6, E Höller2,3, J Levin2,7, U Müller8, S Schwarz2,3, T W Rösler2,3, K Schweyer2,3, G U Höglinger9,10. 1. Klinisches Institut für Neurologie, Medizinische Universität Wien, Wien, Österreich. 2. Klinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland. 3. Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Technische Universität München (TUM), Feodor-Lynen Str. 17, 81377, München, Deutschland. 4. Klinik für Nuklearmedizin und Klinik für Neurologie, Universitätsklinik Köln, Köln, Deutschland. 5. Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE) Bonn/Köln, Köln, Deutschland. 6. Institut für Neurowissenschaften und Medizin, Forschungszentrum Jülich, Jülich, Deutschland. 7. Klinik für Neurologie, Klinikum der Ludwig Maximilians Universität München, München, Deutschland. 8. Institut für Humangenetik, Universität Gießen, Gießen, Deutschland. 9. Klinik für Neurologie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland. Guenter.Hoeglinger@dzne.de. 10. Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE), Technische Universität München (TUM), Feodor-Lynen Str. 17, 81377, München, Deutschland. Guenter.Hoeglinger@dzne.de.
Abstract
BACKGROUND: The microtubule-associated tau protein is the defining denominator of a group of neurodegenerative diseases termed tauopathies. OBJECTIVE: Provide a timely state of the art review on recent scientific advances in the field of tauopathies. MATERIAL AND METHODS: Systematic review of the literature from the past 10 years. RESULTS: Tau proteins are increasingly being recognized as a highly variable protein, underlying and defining a spectrum of molecularly defined diseases, with a clinical spectrum ranging from dementia to hypokinetic movement disorders. Genetic variation at the tau locus can trigger disease or modify disease risk. Tau protein alterations can damage nerve cells and propagate pathologies through the brain. Thus, tau proteins may serve both as a serological and imaging biomarker. Tau proteins also provide a broad spectrum of rational therapeutic interventions to prevent disease progression. This knowledge has led to modern clinical trials. CONCLUSION: The field of tauopathies is in a state of dynamic and rapid progress, requiring close interdisciplinary collaboration.
BACKGROUND: The microtubule-associated tau protein is the defining denominator of a group of neurodegenerative diseases termed tauopathies. OBJECTIVE: Provide a timely state of the art review on recent scientific advances in the field of tauopathies. MATERIAL AND METHODS: Systematic review of the literature from the past 10 years. RESULTS: Tau proteins are increasingly being recognized as a highly variable protein, underlying and defining a spectrum of molecularly defined diseases, with a clinical spectrum ranging from dementia to hypokinetic movement disorders. Genetic variation at the tau locus can trigger disease or modify disease risk. Tau protein alterations can damage nerve cells and propagate pathologies through the brain. Thus, tau proteins may serve both as a serological and imaging biomarker. Tau proteins also provide a broad spectrum of rational therapeutic interventions to prevent disease progression. This knowledge has led to modern clinical trials. CONCLUSION: The field of tauopathies is in a state of dynamic and rapid progress, requiring close interdisciplinary collaboration.
Authors: Zeshan Ahmed; Gabor G Kovacs; Eileen H Bigio; Herbert Budka; Dennis W Dickson; Isidro Ferrer; Bernardino Ghetti; Giorgio Giaccone; Kimmo J Hatanpaa; Janice L Holton; Keith A Josephs; James Powers; Salvatore Spina; Hitoshi Takahashi; Charles L White; Tamas Revesz Journal: Acta Neuropathol Date: 2013-08-31 Impact factor: 17.088
Authors: Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger Journal: Lancet Neurol Date: 2017-06-13 Impact factor: 44.182
Authors: Jochen Hammes; Gérard N Bischof; Kathrin Giehl; Jennifer Faber; Alexander Drzezga; Thomas Klockgether; Thilo van Eimeren Journal: Mov Disord Date: 2016-08-01 Impact factor: 10.338
Authors: Günter U Höglinger; Hans-Jürgen Huppertz; Stefan Wagenpfeil; María V Andrés; Vincente Belloch; Teresa León; Teodoro Del Ser Journal: Mov Disord Date: 2014-01-31 Impact factor: 10.338
Authors: L Donker Kaat; A J W Boon; A Azmani; W Kamphorst; M M B Breteler; B Anar; P Heutink; J C van Swieten Journal: Neurology Date: 2009-05-20 Impact factor: 9.910
Authors: Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto Journal: Lancet Neurol Date: 2014-05-27 Impact factor: 44.182
Authors: Maria Stamelou; Alexander Reuss; Ulrich Pilatus; Jörg Magerkurth; Petra Niklowitz; Karla M Eggert; Andrea Krisp; Thomas Menke; Carmen Schade-Brittinger; Wolfgang H Oertel; Günter U Höglinger Journal: Mov Disord Date: 2008-05-15 Impact factor: 10.338
Authors: Maria Stamelou; Gesine Respondek; Nikolaos Giagkou; Jennifer L Whitwell; Gabor G Kovacs; Günter U Höglinger Journal: Nat Rev Neurol Date: 2021-08-23 Impact factor: 42.937